Degree of Recruitment of DOT1L to MLL-AF9 Defines Level of H3K79 Di- and Tri-methylation on Target Genes and Transformation Potential  by Kuntimaddi, Aravinda et al.
ArticleDegree of Recruitment of DOT1L toMLL-AF9Defines
Level of H3K79 Di- and Tri-methylation on Target
Genes and Transformation PotentialGraphical AbstractHighlightsd DOT1L has three interaction sites with AF9
d DOT1L-AF9 complex forms a mixed alpha-beta structure
similar to the AF4-AF9 complex
d Blocking DOT1L binding to MLL-AF9 causes loss of serial
replating capability
d Differential H3K79me2 and me3 loss is observed on subsets
of MLL-AF9 target genesKuntimaddi et al., 2015, Cell Reports 11, 808–820
May 5, 2015 ª2015 The Authors
http://dx.doi.org/10.1016/j.celrep.2015.04.004Authors
Aravinda Kuntimaddi,
Nicholas J. Achille, ...,
Nancy J. Zeleznik-Le, John H. Bushweller
Correspondence
nzelezn@luc.edu (N.J.Z.-L.),
jhb4v@virginia.edu (J.H.B.)
In Brief
The interaction of DOT1L with the MLL-
AF9 oncogene is critical for
leukemogenesis. Kuntimaddi et al.
demonstrate that MLL-AF9 binds to three
sites within DOT1L and present the
DOT1L-AF9 complex structure. The level
of DOT1L recruitment to MLL-AF9 is
shown to define transformation potential
through altered epigenetic control of
MLL-AF9 target genes.
Cell Reports
ArticleDegree of Recruitment of DOT1L to MLL-AF9
Defines Level of H3K79 Di- and Tri-methylation
on Target Genes and Transformation Potential
Aravinda Kuntimaddi,1 Nicholas J. Achille,2 Jeremy Thorpe,3 Alyson A. Lokken,2 Ritambhara Singh,3
Charles S. Hemenway,4 Mazhar Adli,3 Nancy J. Zeleznik-Le,2,5,* and John H. Bushweller1,5,*
1Department of Molecular Physiology and Biological Physics, University of Virginia, Charlottesville, VA 22908, USA
2Oncology Institute, Department of Medicine, Loyola University Chicago, Maywood, IL 60153, USA
3Department of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, VA 22908, USA
4Oncology Institute, Department of Pediatrics, Loyola University Chicago, Maywood, IL 60153, USA
5Co-senior author
*Correspondence: nzelezn@luc.edu (N.J.Z.-L.), jhb4v@virginia.edu (J.H.B.)
http://dx.doi.org/10.1016/j.celrep.2015.04.004
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARY
The MLL gene is a common target of chromosomal
translocations found in human leukemia. MLL-fusion
leukemia has a consistently poor outcome. One of
the most common translocation partners is AF9
(MLLT3). MLL-AF9 recruits DOT1L, a histone 3 lysine
79 methyltransferase (H3K79me1/me2/me3), leading
to aberrant gene transcription. We show that DOT1L
has three AF9 binding sites and present the nuclear
magnetic resonance (NMR) solution structure of a
DOT1L-AF9 complex. We generate structure-guided
point mutations and find that they have graded ef-
fects on recruitment of DOT1L to MLL-AF9. Chro-
matin immunoprecipitation sequencing (ChIP-seq)
analyses of H3K79me2 and H3K79me3 show that
graded reduction of the DOT1L interaction with
MLL-AF9 results in differential loss of H3K79me2
and me3 at MLL-AF9 target genes. Furthermore,
the degree of DOT1L recruitment is linked to the level
of MLL-AF9 hematopoietic transformation.INTRODUCTION
The mixed lineage leukemia (MLL) protein is a histone 3 lysine 4
methyltransferase that positively regulates gene expression
during development. TheMLL gene is a common target of chro-
mosomal translocations found in acute leukemias where an
N-terminal fragment of MLL is fused to over 70 different nuclear,
cytoplasmic, or membrane partners (Meyer et al., 2013). MLL
leukemia accounts for up to 10% of acute myeloid leukemia
(AML) and acute lymphoblastic leukemia (ALL) but is over-repre-
sented in infants and adults treated with drugs that target DNA
topoisomerase II (Muntean and Hess, 2012).
MLL-fusion partners AF9, ENL, and AF4 account for over two-
thirds ofMLL rearrangements (Krivtsov andArmstrong, 2007) and
have been shown to associate with each other as members of808 Cell Reports 11, 808–820, May 5, 2015 ª2015 The Authorstranscriptional elongation complexes, suggesting that misregula-
tionof transcriptional elongation is a commonmechanism inMLL-
dependent leukemogenesis (Biswas et al., 2011; Lin et al., 2010;
Mohan et al., 2010; Mueller et al., 2007; Yokoyama et al., 2010).
The N-terminal portions of these fusion partner proteins are lost
in MLL rearrangements, whereas C-terminal domains are re-
tained; in AF9, this domain is referred to as the ANC1 homology
domain (AHD). This enables the MLL-fusion protein to constitu-
tively interact with members of these transcriptional elongation
complexes. In particular, the AF9 AHD can recruit AF4 family
members leading to the subsequent phosphorylation of RNA po-
lymerase II via P-TEFb (Bitoun et al., 2007; Erfurth et al., 2004), as
well as DOT1L, a methyltransferase responsible for histone 3
lysine 79 (H3K79)methylation, amark associatedwith active tran-
scription (Steger et al., 2008; Zhang et al., 2006). The constitutive
recruitment of these proteins by MLL-AF9, combined with the
gene-specific recognition binding domains of the N-terminal
portion of MLL, leads to dysregulated expression of MLL target
genes such as HOXA9 and MEIS1, decreased differentiation,
and increased self-renewal (Muntean and Hess, 2012).
A number of in vitro, in vivo, and small molecule inhibitor
studies have recently shown that DOT1L is essential for MLL-re-
arranged leukemia. DOT1L is the only known enzyme to catalyze
the mono-, di-, and tri- methylation of the globular domain of
histone H3 at lysine 79 (H3K79me1, H3K79me2, H3K79me3).
This enzyme plays a role in many different cellular processes
from cell-cycle regulation to differentiation and has been impli-
cated in leukemogenesis, kidney injury, and cardiac disorders
(reviewed in Nguyen and Zhang, 2011). DOT1L-mediated
H3K79 methylation marks are enriched in the gene body and
are coupled with gene transcription (Steger et al., 2008). Occu-
pancy of the MLL-AF9 fusion protein is correlated with elevated
H3K79me2 levels at target genes (Bernt et al., 2011; Nguyen
et al., 2011). A small-molecule inhibitor, EPZ-5676, that inhibits
the enzymatic activity of DOT1L leads to loss of H3K79me2 at
MLL-fusion loci and has shown some efficacy in mouse models
of MLL-fusion leukemia (Daigle et al., 2013).
The protein-protein interaction between AF9 and DOT1L
has been roughly mapped (Biswas et al., 2011; Shen et al.,
2013;Yokoyamaetal., 2010;Zhangetal., 2006), but there is a lack
of structural characterization of this interaction and functional ef-
fects of the direct recruitment of DOT1L. To that end, we now
show that there are three separate regions in DOT1L that interact
with AF9 and fold into structurally similar complexes.Wealso pre-
sent the first structure of a DOT1L-AF9 complex. Using structure-
guided mutagenesis, we develop point mutations that reduce
DOT1L binding to AF9 in a gradedmanner. Functional character-
ization of these point mutations in the context of MLL-AF9 shows
that the degree of DOT1L recruitment to theMLL-AF9 fusion pro-
tein differentially affectsH3K79me2 andH3K79me3 levels at spe-
cific target genes and that direct recruitment ofDOT1L is essential
for the transforming potential of MLL-AF9.
RESULTS
DOT1L Has Three Separate Motifs for Binding AF9 that
Form Structurally Similar Complexes
Previous biochemical studies have broadly determined regions of
both DOT1L (aa 479–659 and aa 828–1095) as well as AF9 (aa
495–568),whichmediate their interaction (Biswaset al., 2011; Yo-
koyamaetal., 2010;Zhangetal., 2006). The regionofAF9defined,
referred to as theANC1homologydomain or AHD, is the same re-
gion for which we have recently determined the structure of an
AF4 peptide-AF9 complex (Leach et al., 2013). Co-expression
of the previously delineated regions of AF9 and DOT1L with one
another resulted in stable complexes but very poor nuclear mag-
netic resonance (NMR) spectra. To define appropriate regions to
utilize for structural studies, we expressed deletion constructs
and analyzed them using heteronuclear triple resonance NMR
to assign resonances and {15N}-1H heteronuclear NOEmeasure-
ments toassess thedynamicbehaviorof the residues, i.e., identify
what residues were flexible and remove them. This process led
not only to high-quality 15N-1H HSQC NMR spectra, but also the
identification of three separate DOT1L motifs for binding with
AF9: site 1 (aa 628–653), site 2 (aa 863–878), and site 3 (aa 877–
900) (Figures 1A and 1B). For AF9, we identified a functional
domain (aa 499–568) that produces optimal NMR spectra with
all three DOT1L motifs. The 15N-1H HSQC spectra of the three
complexes of AF9 with the different DOT1L motifs show a strong
similarity (Figure 1B). Indeed, comparison of the individual AF9
amide chemical shifts among the three complexes shows rela-
tively small changes (Figure 1C). As chemical shifts are highly
dependent on protein structure and local environment, this indi-
cates thatAF9 folds in a very similarmannerwitheachof thesepa-
rate DOT1L binding motifs.
Comparison of the DOT1L motifs across species shows that
they are conserved (Figures S1A and S1B) and exhibit a periodic
pattern of hydrophobic residues consistent with that of a b strand
(Figures 1A and 1E). The DOT1L (site 2) and (site 3) motifs are
nearly identical, with the exception of a bulkier isoleucine residue
in the third position of the DOT1L (site 2) binding site as opposed
to a valine in DOT1L (site 3) (Figure 1E). Fluorescence polariza-
tion based binding studies revealed a 17-fold weaker affinity
for DOT1L (site 2) with AF9 (Figures 1D and 1E). In the same po-
sition, DOT1L (site 1) has a bulkier leucine residue as well as a
leucine in the tenth position, as opposed to a valine, as seen in
the other two binding sites (Figures 1A and 1E). Our bindingstudies show weak affinity for this binding site (Kd > 2,000 nM)
(Figures 1D and 1E). As ENL, another fusion partner with MLL,
is highly homologous to AF9, we tested binding of each of these
DOT1L peptides with ENL, which yielded similar binding affinities
for ENL as seen for AF9 (Figures S2A and S2B).
Intriguingly, DOT1L (site 2) and DOT1L (site 3) are high-affinity
binding motifs, which are only separated by a 4-amino-acid
spacer sequence; i.e., they form a repeat motif in DOT1L (Fig-
ure 1A). To test whether it was sterically feasible for two AF9
AHDs to bind simultaneously to both of these DOT1L sites, we
co-expressed the entire repeat motif consisting of both DOT1L
(sites 2 and 3) (aa 863–900) with the AF9 AHD. Size-exclusion
chromatography shows the formation of a complex consistent
with two AF9 AHDs bound (Figures 1F and 1G). The 15N-1H
HSQC NMR spectrum of this complex shows that there are
duplicate AF9 peaks for each AF9 residue, which overlay very
closely with the AF9 amide resonances from the DOT1L (site
2)—AF9 and DOT1L (site 3)—AF9 individual complexes (Fig-
ure 1H). Additionally, the DOT1L resonances in this entire repeat
motif overlap with the resonances from each of the individual
DOT1L (site 2) and (site 3) complexes, indicating that the com-
plexes on the repeat motif closely resemble those of the individ-
ual complexes (Figure 1H).
We have previously shown that the C-terminal domain of AF9
is an intrinsically disordered protein that folds into structured
complexes upon binding partner proteins (Leach et al., 2013).
Each of the DOT1L sites interacting with AF9 is predicted to be
disordered (Figure S1C), suggesting that there is a mutual syner-
gistic folding between AF9 and DOT1L at each of these binding
sites. Our binding measurements of DOT1L (site 2) with AF9
yielded Kd values significantly different from those reported in
a recent publication that biochemically mapped the interaction
of this particular DOT1L site with AF9 but did not identify the in-
teractions of the other DOT1L sites (Shen et al., 2013). As is the
case with many intrinsically disordered proteins, the AF9 AHD
has a propensity to aggregate, requiring significant care in the
concentrations and conditions employed for binding measure-
ments, perhaps suggesting a rationale for the difference in the
measured binding affinities.
NMR Solution Structure of the DOT1L-AF9 Complex
We solved the NMR solution structure of the highest affinity
DOT1L-AF9 complex (DOT1L site 3 877–900) (PDB ID: 2MV7)
using dihedral angle, NOE, and residual dipolar coupling
(RDC) restraints without any significant constraint violations (Ta-
ble S1). The NMR ensemble of the ten lowest energy structures
of DOT1L-AF9 shows a well-formed complex (Figure 2A). The
DOT1L-AF9 complex forms a mixed alpha-beta structure, and
the DOT1L residues (879–884) form a b strand followed by a b
turn (aa 885–888). Immediately C-terminal, residues 889–895
make contacts with AF9 but not as significant as the preceding
DOT1L residues, and the following C-terminal amino acids, 896–
900, are unstructured (Figure 2B). The interface between the two
proteins is largely hydrophobic, as DOT1L L879, V881, I883,
L885, and V888 are critical hydrophobic residues that are buried
within the DOT1L-AF9 interface (Figure 2C). AF9 forms three he-
lices around the DOT1L peptide (a1, a2, a3) and a b hairpin (b1
and b2), which forms a three-stranded antiparallel b sheet withCell Reports 11, 808–820, May 5, 2015 ª2015 The Authors 809
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Figure 1. DOT1L Has Three Separate Sites of Interaction with AF9
(A) The minimal interacting sites of DOT1L, site 1 (purple), site 2 (blue), and site 3 (black) with MLL-AF9 (aa 499–568). Identified in red are the similar motifs making
up each of the binding sites.
(B) 15N-1H HSQC NMR spectra of the co-expressed minimal interacting sites of DOT1L with AF9. Labeled in red are the chemical shifts of hydrophobic residues
within the separate DOT1L motifs compared to that of the same residues within DOT1L site 3 (displayed as brackets).
(legend continued on next page)
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Figure 2. Structure of the DOT1L-AF9
Complex
(A) Ensemble of the ten lowest energy conformers.
DOT1L is shown in red and AF9 in blue.
(B) Cartoon representation of the lowest energy
conformer. DOT1L (red) forms a b strand, along
with the b hairpin from AF9 (blue), while AF9
additionally forms three a helices.
(C) Surface representation of the DOT1L-AF9
complex. Shown are hydrophobic residues from
DOT1L that are buried within the protein-protein
interface and are critical for the interaction.
(D) Superposition of DOT1L-AF9 with our previ-
ously solved AF4-AF9 complex (PDB code: 2LM0;
AF9 is purple and AF4 is white). RMSD = 1.4 A˚.the b strand from DOT1L; the C terminus of AF9 (aa 563–568) is
unstructured (Figure 2B). While the chemical shift differences
are minimal between the three DOT1L-AF9 complexes, larger
chemical shift changes are seen around AF9 residues adjacent
to the DOT1L peptide (aa 537–547) (Figures 1C and S1D). Our
NMR data and chemical shift mapping results suggest that the
three sites of DOT1L all form the same mixed alpha-beta struc-
ture. The structure of the DOT1L-AF9 complex is very similar to
our previously solved AF4-AF9 complex (PDB ID: 2LM0). Both
DOT1L and AF4 share a similar consensus hydrophobic motif
(Figure S3A) and superposition of the backbone residues yields
an RMSD of 1.4 A˚ (Figure 2D). According to the Dali server, the
BRD4 ET domain (PDB ID: 2JNS) has a similar helical fold to the
helical portion of AF9 (RMSD = 3.98 A˚) (Figure S3B).
Point Mutations in AF9 and DOT1L Differentially
Attenuate the Multiple DOT1L-AF9 Interactions
The DOT1L-AF9 structure was used as a basis to rationally
design point mutations within both proteins to disrupt this pro-
tein-protein interaction. We identified an AF9 residue, D546,(C) Chemical shift difference between AF9 amide NH resonances from the DOT1L (site 1)-AF9 complex (purple
to DOT1L (site 3)-AF9.
(D) Results of fluorescence polarization assay for determination of the Kd values for binding of MBP-AF9 AH
bars show SDs of replicate measurements.
(E) Table of Kd values for the three DOT1L sites with their respective primary sequences. Shown in red a
Highlighted is the third position of this motif that differs between each of the binding sites.
(F) Size exclusion profile of complexes of AF9 with DOT1L site 2 (blue), DOT1L site 3 (black), and with the repe
with protein standards (gray). The size of AF9 bound to the DOT1L repeat motif is consistent with that of tw
(G) Cartoon depicting that two separate AF9 proteins can bind simultaneously to both high-affinity DOT1L b
(H) 15N-1H HSQC NMR spectrum of DOT1L repeat motif (aa 863–900; red) bound to AF9. Shown are examp
same AF9 amide peak from DOT1L site 2, AF9 (blue), and DOT1L site 3, AF9 (black).
Cell Reports 11, 808which is part of the AF9 b-hairpin (b2)
and is in position to make an electro-
static interaction with DOT1L K878 (Fig-
ure 3A). We mutated this residue to
arginine (denoted as D546R) to create
charge repulsion. The D546R AF9
mutant significantly reduces binding to
both DOT1L high-affinity sites (Figures
3B and 3C), cannot pull down a DOT1L
construct comprised of the high-affinityDOT1L binding sites (Figure 3D), and has significantly
decreased binding to full-length DOT1L (Figure S4A). Interest-
ingly, the AF9 D546R mutant protein is still capable of immuno-
precipitating the low-affinity Dot1L (site 1) (Figure S4A). We also
employed a previously described AF9 D544R mutation (Lokken
et al., 2014). D544 is also a part of the AF9 b-hairpin (b2) and
makes direct contacts with DOT1L S882 (Figure 3A). Interest-
ingly, the D544R mutation shows a pronounced effect on bind-
ing to DOT1L (site 3) and a limited effect on binding to DOT1L
(site 2) (Figures 3B and 3C). Consistent with this, the D544R
mutant protein has been shown to still pull down DOT1L
(site 1) (Lokken et al., 2014), has a slightly diminished ability
to pull down DOT1L (sites 2 and 3) (Figures 3D and 3E), and still
interacts with full-length Dot1L (Figure S4B). As the binding of
wild-type and mutant AF9 proteins with the DOT1L (site 1) is
extremely weak, we were unable to quantify any differences
in binding to this site using our FP assays (Figure 3C).
The structure of the DOT1L-AF9 complex that we have deter-
mined and our previously described AF4-AF9 structure (Leach
et al., 2013) show that both AF4 and DOT1L bind in the same) and DOT1L (site 2)-AF9 complex (blue) compared
D to each of the three DOT1L binding motifs. Error
re hydrophobic residues of these DOT1L motifs.
at element (aa 863–900; red) bound to AF9 overlaid
o AF9 proteins bound to the repeat motif.
inding sites.
les of two AF9 resonance peaks, overlaid with the
–820, May 5, 2015 ª2015 The Authors 811
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Figure 3. Identification of Mutations that Disrupt the DOT1L-AF9 Interactions
(A) Left: cartoon representation of the DOT1L-AF9 structure showing D544 and D546, located on the AF9 b hairpin, that make direct interactions with DOT1L.
Right: Electrostatic surface representation depicting that D546 (AF9) and K878 (DOT1L) make a charge-charge interaction.
(B) Results of fluorescence polarization assays for determination of the Kd values for binding of MBP-AF9 AHD (WT), MBP-AF9 AHD (D544R) (top), and MBP-AF9
AHD (D546R) (bottom), to DOT1L binding motifs 2 and 3. Error bars show SDs of replicate measurements.
(C) Table of Kd values for binding of MBP-AF9 AHD (WT), MBP-AF9 AHD (D544R), and MBP-AF9 AHD (D546R) to the DOT1L binding motifs. MBP-AF9 (D546R)
significantly affects binding of both DOT1L high binding sites 2 and 3, whereas MBP-AF9 (D544R) has a more significant effect only on site 3.
(D and E) Co-IP data of D546R and D544R with the high-affinity sites of DOT1L.
(F) Surface representation of the DOT1L (red)-AF9 (blue) complex. Side chains of two buried hydrophobic residues from DOT1L, V881 and I883, are shown in
yellow.
(G) Two alanine mutations of similarly positioned hydrophobic residues within each DOT1L binding site used to disrupt AF9 binding.
(H) Results of fluorescence polarization assay for MBP-AF9 AHD titrated into fluorescently tagged DOT1L peptide with (V881A, I883A), showing no binding. Error
bars show SDs of replicate measurements.site on AF9, consistent with previous biochemical studies
showing that the binding of the two is mutually exclusive (Biswas
et al., 2011; Yokoyama et al., 2010). Based on the similarity of the812 Cell Reports 11, 808–820, May 5, 2015 ª2015 The AuthorsNMR spectra of AF9 complexes with BCoR and CBX8 (Leach
et al., 2013), it is likely these partners also bind in the same
site. Due to this, it is challenging to identify point mutations in
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Figure 4. The Level of DOT1L Recruitment
toMLL-AF9 Defines the Degree of Serial Re-
plating Capability
(A) Results of serial replating assays for MLL-AF9
(wt), MLL-AF9 (D544R), and MLL-AF9 (D546R).
Cells expressing MLL-AF9 (WT) consistently re-
plated over a period of 4 weeks. Cells expressing
MLL-AF9 (D544R) show a reduction in serial re-
plating ability. Cells expressing MLL-AF9 (D546R)
show a complete abrogation of serial replating
ability. Error bars show SDs of replicate mea-
surements.
(B) Bright-field and Wright-Giemsa images of
MLL-AF9 (WT) colonies show large, tight colonies
(top) containing mostly cells with a blast-like
morphology (bottom), whereas MLL-AF9(D544R)
have more dispersed colonies, some with
tight centers, and more differentiated cells.
Strikingly, MLL-AF9(D546R) colonies are com-
pletely diffuse, with almost exclusively differen-
tiated cells.
(C) Results of methylcellulose colony assays from
MLL-AF9-transformed Dot1lfl/D cells, co-trans-
duced with wild-type or mutant Dot1l, either with
or without Cre recombinase.
(D) Dot1l genomic status was examined by PCR at
day 7 after methylcellulose culture of MLL-AF9- or
E2A-PBX-transformed Dot1lfl/D cells, expressing
the indicated exogenous proteins. Dark arrow-
head, floxed allele (510 bp); open arrowhead,
deleted allele (378 bp). NTC, non-template control.
(E) Wright-Giemsa images of cells from Dot1l
complementation methylcellulose colony experi-
ment, showing ability of exogenous Dot1l (WT),
but not Dot1l (mut 1 + 2 + 3) to rescue blast-like
morphology of MLL-AF9-transformed Dot1lfl/D
cells.AF9 that can selectively inhibit the binding of specific partner
proteins. Both of our AF9 mutants indeed have effects on the
binding of other AF9 interacting partners (Figures S4C and
S4D), and notably we see an increase in full-length CBX8 binding
with our D546R mutant (Figure S4D). As binding to DOT1L and
AF4 is presumed to be most critical for gene activation, it is
important to note that the effects of the D544R and D546R mu-
tations on AF4 binding are similar, so a comparison of the biolog-
ical effects of these two mutations in the context of MLL-AF9
should give meaningful insights into the role of recruitment of
DOT1L, in particular.
In order to complement the biological readouts we obtained
with the AF9 D544R and D546Rmutations, we have also charac-
terized mutations in DOT1L that selectively inhibit binding to
each of the three AF9 binding motifs. Mutation of two DOT1L
hydrophobic residues, V881 and I883, that are buried within
the protein-protein interface (Figure 3F), to alanine (Figure 3G),
denoted as V881A, I883A, completely abrogates binding of
DOT1L (site 3) to AF9 (Figure 3H). To disrupt the binding to
each of the remaining DOT1L binding sites, we made similar mu-
tations of the corresponding DOT1L hydrophobic residues at site
1 (L640A, I642A) and site 2 (I867A, I869A) (Figures S5A and S5B).
To this end, we created a series of DOT1Lmutants that disruptedthe three DOT1L-AF9 interactions alone as well as in various
combinations.
Disruption of DOT1L Recruitment via High-Affinity
Binding Sites to MLL-AF9 Leads to Dramatic Losses in
Hematopoietic Transformation
We used serial colony formation assays to assess the biological
impact of differentially disrupting the DOT1L interactions with
MLL-AF9. Briefly, hematopoietic progenitor cells isolated from
mouse bone marrow were transduced with retrovirus express-
ing either wild-type MLL-AF9 (WT) or the mutants MLL-AF9
(D544R) and MLL-AF9 (D546R). Cells were then serially replated
on a weekly basis over a period of 4 weeks. Colony-forming
ability shows a gradient between cells expressing MLL-AF9
(WT), which efficiently replated for 4 weeks, the MLL-AF9
(D544R) mutant, which exhibited reduced colony formation in
agreement with our recent publication (Lokken et al., 2014),
and MLL-AF9 (D546R), which showed a more dramatic loss in
colony formation (Figure 4A). Both of the mutants showed
more diffuse colonies comprised of fewer cells compared to
the dense, compact colonies formed by MLL-AF9 (WT) cells
(Figure 4B). Cytospin and Wright-Giemsa staining indicate that
MLL-AF9 (WT) expressing cells exhibit a blast-like morphology,Cell Reports 11, 808–820, May 5, 2015 ª2015 The Authors 813
and cells expressing MLL-AF9 (D546R) appear to be differenti-
ated (Figure 4B).
A complementary experiment was performed to determine
whether there were functional differences between the individual
AF9-binding sites of DOT1L. Bone marrow progenitor cells iso-
lated from conditional Dot1l deletion mice transformed with
MLL-AF9 (Chang et al., 2010) were co-transduced with retrovi-
ruses expressing GFP-wild-type DOT1L or GFP mutant DOT1L
plus either mCherry-Cre or mCherry alone. GFP/mCherry dou-
ble-positive cells were sorted and assessed for colony-forming
ability. Deletion of endogenous Dot1l significantly decreased
colony-forming ability (Figure 4C, KO+ versus WT+), as we
have shown previously (Chang et al., 2010). Remaining colonies
result from expansion of cells that escaped Cre-mediated dele-
tion (Figure 4D). Because there is such strong selective pressure
for MLL-AF9-transformed cells to retain functional Dot1l expres-
sion, unless exogenous functional DOT1L is provided, only cells
that retain endogenous Dot1l grow and expand, as demon-
strated by the presence of the undeleted Dot1l allele (Figure 4D,
upper gel). This dependence was not true for E2A-PBX-trans-
formed cells, aswe have shown previously (Figures 4D and S5C).
To further determine the functional significance of each AF9-
binding site in DOT1L, mutant versions of DOT1L were exoge-
nously provided in combination with deletion of the endogenous
Dot1l. Mutations that disrupt each AF9-binding site in DOT1L
individually cause reduced colony formation, but only themutant
DOT1L (site 2) rises to statistical significance. With each single
site mutant, there is no selection bias for cells retaining the
endogenous Dot1l allele (Figure 4D). Simultaneous mutation of
two sites proved to be particularly interesting. Mutation of sites
1 + 2 showed no decrease in colony-forming ability compared
to wild-type DOT1L, but rather an increase. Mutation of sites
1 + 3 was no different than when no exogenous DOT1L was
added. Although mutation of sites 2 + 3 did not demonstrate a
statistically different colony-forming ability, remaining colonies
were due to expansion of cells retaining the endogenous Dot1l
allele (Figure 4D). Thus, DOT1L with both sites 2 + 3 mutated
does not confer colony-forming capacity to MLL-AF9-trans-
formed cells. Simultaneously blocking all three DOT1L binding
sites with alanine mutations shows colonies with differentiated
morphology (Figure 4E) and a loss in colony formation similar
to that when no exogenous DOT1L was provided (Figure 4C).
This demonstrates that high-affinity DOT1L binding to AF9 is
necessary for the colony-forming ability of MLL-AF9, and that
the multiple binding sites act in concert with one another.
MLL-AF9 (D544R) andMLL-AF9 (D546R) Display Distinct
Patterns of Loss of H3K79me2 and H3K79me3 on a
Select Set of Genes
To assess the epigenetic effects of disrupting the multiple
DOT1L and MLL-AF9 interactions, we used chromatin immuno-
precipitation followed by next-generation sequencing (chro-
matin immunoprecipitation sequencing [ChIP-seq]) to identify
the genome-wide localization of H3K79me2 and H3K79me3 in
primary hematopoietic progenitor cells expressing wild-type
or mutant MLL-AF9. We analyzed H3K79me2 and H3K79me3
profiles and compared both MLL-AF9 (D544R) and MLL-AF9
(D546R)mutants to wild-typeMLL-AF9 (WT). There weremodest814 Cell Reports 11, 808–820, May 5, 2015 ª2015 The Authorschanges in individual genes for H3K79me2 and H3K79me3
marks when comparing the MLL-AF9 (D544R) mutant to MLL-
AF9 (WT), but none rising to the level of significance (FDR <
0.1). In contrast, our MLL-AF9 (D546R) data show that with
complete disruption of the high-affinity DOT1L interaction to
MLL-AF9, 44 genes display a significant loss of the H3K79me2
mark, and 42 genes show a reduction of the H3K79me3 mark
(FDR <0.1) compared to MLL-AF9 (WT) data (Figure 5A; Fig-
ure S6). A majority (31 out of 44 for H3K79me2 and 30
out of 42 for H3K79me3) of these genes are direct targets of
MLL-AF9, as defined by a previous MLL-AF9 ChIP-seq study
(Figure 5A) (Bernt et al., 2011). A number of the identified genes
with both decreased H3K79me2 and H3K79me3 have been
shown to play a role in MLL-rearranged leukemia such as
Hoxa9, Meis1, Runx2, and Jmjd1C (Figures 5A, 5B, S6A, and
S6B; Table S2). There are not many genes with differentially
affected changes in only H3K79me2 or H3K79me3, but not
both, with the MLL-AF9(D546R) mutant. Of note is Cdk6, which
shows a significant decrease in the H3K79me3 mark, but not
H3K79me2, and has recently been shown to be important for
MLL-rearranged leukemia (Figure S6D) (Placke et al., 2014). In
contrast, Eya1 shows decreased H3K79me2 without significant
change in H3K79me3, to the level of detection (Figure S6C),
and is overexpressed in MLL leukemia (Wang et al., 2011).
Mapping the genome-wide distribution of H3K79me2 and
H3K79me3 marks across the set of genes that we found to be
changed as a result of disrupting the DOT1L interaction with
MLL-AF9 demonstrated no significant decrease in H3K79me2
levels for MLL-AF9 (D544R) but a substantial reduction for MLL-
AF9 (D546R) (Figure5C). Interestingly, adifferentpatternof effects
on H3K79me3 is observed. The H3K79me3 data show that
MLL-AF9 (D544R) levels significantly decrease in the H3K79me3
profile plot compared to wild-type (Wilcoxon test p value = 0.02)
(Figure 5D), and a complete loss of H3K79me3 is observed for
MLL-AF9 (D546R). Thus, there is a differential effect of the loss
of binding of MLL-AF9 to one or two high-affinity DOT1L binding
motifs on H3K79me2 and H3K79me3 levels at target genes.
Selected H3K79me2 and H3K79me3 Genes Display
Distinct Patterns of Gene Expression in MLL-AF9
(D544R) and MLL-AF9 (D546R) Mutant Cells
Wenext investigatedwhether the differential recruitment of Dot1l
to MLL-AF9 and observed changes in H3K79 di- and tri-methyl-
ation correlated to changes in gene expression levels in selected
genes. To assess this, gene expression levels were determined
by quantitative RT-PCR in primary bonemarrow cells expressing
MLL-AF9, and the MLL-AF9 mutants. We selected genes that
represented a decrease in both H3K79me2 and me3 (Hoxa9
and Meis1), a decrease in only H3K79me2 or H3K79me3 (Eya1
and Cdk6, respectively), or no change in either (Myb and Gfi1)
(Figures S6E and S6F), with our MLL-AF9 (D546R) mutant (Fig-
ure 6A). All of these genes are MLL-AF9 targets (Bernt et al.,
2011) and have previously been shown to be involved in leuke-
mogenesis (Khandanpour et al., 2013; Placke et al., 2014;
Wang et al., 2011).
Interestingly, we observe different patterns of gene expression
for these different selected gene classes (Figure 6). Hoxa9 and
Meis1 both show losses in H3K79me2 and H3K79me3 (Figure 5),
AB
C D
Figure 5. MLL-AF9 (D544R) and MLL-AF9 (D546R) Display Distinct Patterns of Loss of H3K79me2 and H3K79me3 on a Select Set of Genes
(A) Venn diagram overlaying gene sets showing significant loss of H3K79me2 and H3K79me3 marks upon comparison of MLL-AF9 (D546R) with MLL-AF9 (WT)
(FDR < 0.1). Additionally overlaid is the set of genes identified previously by ChIP-seq as direct MLL-AF9 targets (Bernt et al., 2011). Listed to the right are genes
that overlap between the H3K79me2, H3K79me3, and MLL-AF9 direct target data sets.
(B) ChIP-seq profiles of the HOXA cluster and Meis1 both show a loss in the H3K79me2 and H3K79me3 marks with the D546R mutation.
(C) H3K79me2 genomic profile at genes we identified to be significant in Figure 5A shows thatMLL-AF9 (D546R) significantly reducesH3K79me2marks, whereas
there is no difference in the profile between MLL-AF9 (D544R) and MLL-AF9 (WT).
(D) H3K79me3 genomic profile at genes we identified to be significant in Figure 5A shows that MLL-AF9 (D546R) reduces H3K79me3 to background levels, even
lower than observed for the H3K79me2 profile of this samemutant. There is also a significant difference inMLL-AF9 (D544R) andMLL-AF9 (WT) profiles (Wilcoxon
test p value = 0.02).and we observe a graded decrease in expression going from
wild-type MLL-AF9 to MLL-AF9(D544R) to MLL-AF9(D546R)
(Figures 6B and 6C). Gfi1 and Myb show no change in
H3K79me2 and H3K79me3; however, they show different pat-
terns of expression with the mutations. Gfi1 shows no effect
with D544R but decreased expression with D546R (Figure 6D),
whereas Myb shows similar reductions in expression with
both mutations (Figure 6E), suggesting additional mechanisms
of regulation at these genes. Cdk6 only shows losses in
H3K79me3 and shows a similar decrease in expression forboth D544R and D546R mutations (Figure 6F), consistent with
a role for only H3K79me3 at this gene. Interestingly, Eya1 shows
only decreased H3K79me2 but displays the same graded reduc-
tion in expression with the mutations as observed for Hoxa9 and
Meis1 (Figure 6G).
DISCUSSION
It has been established that DOT1L is required for MLL-AF9
leukemogenesis; however, the role of the direct recruitment ofCell Reports 11, 808–820, May 5, 2015 ª2015 The Authors 815
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Figure 6. Gene Expression Data UsingMLL-
AF9 (WT), MLL-AF9 (D544R), and MLL-AF9
(D546R)
(A) Venn diagram depicting genes that were
selected for gene expression analyses.
(B–G) Gene expression data of (B) Hoxa9, (C)
Meis1, (D) Gfi1, (E) Myb, (F) Cdk6, (G) Eya1
from murine bone marrow progenitor cells ex-
pressing MLL-AF9 (WT), MLL-AF9(D544R), or
MLL-AF9(D546R) after 1 week in methylcellulose
culture.DOT1L by MLL-AF9 has not been clearly delineated. Our study
provides important insights into the detailed mechanism and
functional role of the interactions of DOT1L with MLL-AF9. We
have found that DOT1L has three separate AF9 binding sites
and that each separate DOT1L interacting site forms a similarly816 Cell Reports 11, 808–820, May 5, 2015 ª2015 The Authorsstructured DOT1L-AF9 complex. Our
NMR solution structure of the highest af-
finity DOT1L-AF9 complex is very similar
to that of AF4-AF9, as both form nearly
identical mixed a/b structures. Indeed,
our results provide a structural basis for
findings that interactions of AF9 aremutu-
ally exclusive with its different binding
partners (Biswas et al., 2011; Leach
et al., 2013; Yokoyama et al., 2010).
The AF9 AHD is intrinsically disordered,
a characteristic seen in numerous sig-
naling hubs, potentially allowing the hub
protein to gain kinetic advantages from
the binding of one interacting partner
and its exchange for another (Dyson and
Wright, 2005). Each of the AF9 binding
proteins contains a similar binding motif,
consistent with the observation that
many proteins are enriched with short
linear motifs, or eukaryotic linear motifs,
which are small intrinsically disordered re-
gions of functional modules from three to
11 amino acid residues (Tompa et al.,
2014). These play a large role in many
hub proteins that regulate diverse cellular
processes. Eukaryotic linear motifs are
enriched with post-translational modifica-
tion sites that serve as a means of dy-
namic regulation and control of their
activity (Van Roey et al., 2014). Indeed,
we have previously shown that phosphor-
ylation of AF4 at a site that has been
shown to be phosphorylated in cells
(Beausoleil et al., 2004) reduces its affinity
for AF9 (Leach et al., 2013). Phosphoryla-
tion of serines within each of the DOT1L
binding motifs (aa 643, 868, 882) could
also lead to reduction in binding, but
only S882 has been shown to be phos-phorylated in vivo (Hornbeck et al., 2012). DOT1L is unique
among the AF9 binding partners in that there are multiple
DOT1Lmotifs that bind to AF9, and each is predicted to be disor-
dered. Even though a large number of eukaryotic motifs in intrin-
sically disordered proteins (IDPs) have been characterized in
various diseases, the biological function and necessity of multi-
ple eukaryotic linearmotifs within one protein is only beginning to
be unraveled (Tompa et al., 2014).
While we were successful in identifying two separate AF9
mutations with differential effects on the DOT1L interactions
with AF9, neither is completely specific for the DOT1L-AF9
interaction, and both have varying effects on other AF9 binding
partners. As the structures of the different AF9 complexes are
very similar, it is challenging to make such specific mutations.
It is important to note that co-immunoprecipitation experiments
alone do not necessarily provide sufficient information to deter-
mine lack of effect of a particular mutation on protein interac-
tion. Measurements of the binding affinities of these AF9
mutant proteins with binding partners show that these and
other previously described AF9 (or ENL) mutations (Biswas
et al., 2011; Lokken et al., 2014; Maethner et al., 2013; Tan
et al., 2011) are not completely specific for a single protein part-
ner (Figures S4C and S7). While it is definitely the case that the
full-length proteins may behave differently, our results point out
the importance of having the appropriate quantitative binding
data to meaningfully interpret the biological effects of these
mutations.
We clearly observe that the transforming properties of MLL-
AF9, as measured by colony formation, are affected by the
degree of direct recruitment of DOT1L to MLL-AF9. Partial
disruption of high-affinity DOT1L binding (D544R) reduces col-
ony formation substantially, but complete disruption (D546R)
results in an even greater decrease in colony formation ability.
Individually blocking each DOT1L binding site leads to similar
losses in colony formation, suggesting that individual DOT1L
binding sites can have distinct functional roles. However, we
see the most dramatic reduction in serial replating ability upon
simultaneously blocking multiple DOT1L interactions with MLL-
AF9. Mutation of either all three sites (1 + 2 + 3) or sites (1 + 3)
function similarly to cells without any Dot1l. This suggests an ad-
ditive function of the binding sites. Indeed, morphological data
show that both our MLL-AF9 (D546R) and our Dot1L site (1 +
2 + 3) mutants lead to differentiation of hematopoietic progeni-
tors. Interestingly, mutation of sites (1 + 2) results in significantly
higher colony number than wild-type DOT1L addback. In this
context, it is important to remember that the mutations in
DOT1L will affect not only binding to MLL-AF9, but also binding
to wild-type AF9 and ENL, so the phenotypic output will be the
sumof effects on all three targets; i.e., it is not possible to ascribe
the observed effects only to the MLL-AF9 interaction.
DOT1L is a non-processive, or distributive, enzyme, meaning
that at most one round of methylation can take place in each
encounter with its substrate before the enzyme must dissociate
and re-associate to achieve subsequent rounds of methylation.
As a result of this distributive nature of DOT1L, it has been sug-
gested that there could be a functional redundancy between the
H3K79 methylation marks (Frederiks et al., 2008). In contrast,
several studies have suggested that different methylation
states at H3K79 may have different functions in gene regulation
(Nguyen and Zhang, 2011). H3K79me2 and H3K79me3 in yeast
do not have overlapping chromatin patterns, and, unlike
H3K79me3 levels, which do not vary over the cell cycle,
H3K79me2 levels change (Schulze et al., 2009). We show thatblocking the high-affinity DOT1L interactions with MLL-AF9,
via our MLL-AF9 (D546R) mutant, results in significant losses
of H3K79me2 and H3K79me3 at only a select number of genes,
many of which have already been defined as MLL-AF9 targets.
Additionally, we observe significant losses in the methylation
pattern across the gene body at these genes, and the losses
are more pronounced for the H3K79me3 mark. With the
MLL-AF9 (D544R) mutation, we do observe losses in the
H3K79me3 mark that are significant across the gene body
despite changes in individual genes not rising to the level of sta-
tistical significance, a decrease not seen in the H3K79me2
mark. We hypothesize that losses of the H3K79me3 mark are
directly linked to the presence of multiple sites for binding of
AF9 to DOT1L, particularly the high-affinity repeat motif in
DOT1L. Binding of two (or three) sites on DOT1L to MLL-AF9
would significantly increase the residence time of DOT1L at a
specific site on the chromatin. As the enzyme is distributive, a
longer residence time increases the probability of proceeding
all the way to the H3K79 tri-methylated state (see Figure 7A).
With a reduction in contacts between MLL-AF9 and DOT1L
(D544R mutant), the residence time would be decreased and
the level of H3K79 tri-methylation would be reduced. This may
also explain the more pronounced effect of the D546R mutation
on H3K79me3 versus H3K79me2 across the gene body. Thus,
there is a plausible mechanism for the cell to selectively di- or
tri-methylate genomic sites by using mono- versus di- (or tri-)
valent interaction of DOT1L with AF9 (or ENL) at particular sites
in the genome. As DOT1L is the only known H3K79 methyltrans-
ferase, H3K79 methylation levels reflect DOT1L occupancy;
however, our model will likely require further experimental vali-
dation using techniques such as crosslinking kinetic analyses
(Poorey et al., 2013) to directly assess DOT1L residence time
at specific sites in the genome. However, the lack of a ChIP vali-
dated antibody for native DOT1L will likely require the use of
tagged DOT1L for such experiments.
As shown in Figures 5 and 6, we observe different patterns of
changes in H3K79 methylation marks and in gene expression
for various MLL-AF9 target genes, suggesting an underlying
complexity in the regulation, which has not been fully elucidated.
Indeed, a recent study by Armstrong and co-workers has
shown that the DOT1L-mediated conversion of H3K79me1 to
H3K79me2 is regulated by AF10 (Deshpande et al., 2014).
They showed that AF10 knockout leads to a profound reduction
in H3K79me3 levels and to a lesser but significant decrease in
H3K79me2 at specific Hoxa genes, with concomitant changes
in gene expression. Interestingly, it has been reported that
AF10 directly binds to DOT1L at a site that is in close proximity
to the lowest affinity AF9 binding site (site 1) (Okada et al.,
2005) as well as in proximity to the site where DOT1L has been
reported to bind to the phosphorylated CTD of RNA polymerase
II (Kim et al., 2012).
As AF9 binds both activators (AF4 and DOT1L) and repressors
(CBX8 andBCoR) of gene expression, it suggests that it functions
as a signaling hub that provides different outputs depending on
the binding partner. It is not clear, however, how this ‘‘dance’’
of binding partners is orchestrated. Interestingly, the introduction
of the D546R mutation into MLL-AF9 results in an increase
in CBX8 binding, as measured by co-immunoprecipitationCell Reports 11, 808–820, May 5, 2015 ª2015 The Authors 817
Figure 7. Proposed Model of Protein
Recruitment to MLL-AF9
(A) One binding event of DOT1L to MLL-AF9 leads
to H3K79 di-methylation, but binding of two (or
three) sites on DOT1L to MLL-AF9 would signifi-
cantly increase the residence time of DOT1L at a
specific site on the chromatin. As the number of
binding events of DOT1L to MLL-AF9 increase
from one to two (or three), this increases the resi-
dence time of DOT1L at a specific site on the
chromatin increasing the probability of proceeding
to the H3K79 tri-methylated state.
(B) CBX8 is initially bound to MLL-AF9 leading to a
default transcriptionally repressed state. Recruit-
ment of activators such as DOT1L or AF4 leads to
the displacement of CBX8 from MLL-AF9 leading
to gene activation.(Figure S4D). This is not observed with the D544R mutation,
where only partial loss of DOT1L binding is induced. Apparently,
loss of binding of the co-activators, particularly DOT1L, results in
increased repressor (CBX8) binding. While the exact mechanism
is not yet clear, we would speculate that CBX8 binding to MLL-
AF9 (or AF9) leading to stable transcriptional silencing is the
default state in the absence of activators; the binding of DOT1L
and AF4, in some sequence, relieves this default repressive state
leading to activation of gene expression (Figure 7B). It has been
reported that direct CBX8binding is essential forMLL-AF9 leuke-
mogenesis (Tan et al., 2011). Based on our structure and binding
measurements, the point mutations used in that study (T542A
and T554A) have additional impact on DOT1L and AF4 binding
that was not appreciated at the time (Figure S7B). Further
detailed studies are needed to determine the mechanism of
CBX8-dependence of MLL leukemia.
We have shown that the degree of DOT1L recruitment to MLL-
AF9 defines the level of hematopoietic transformation. Further
studies are necessary to understand similar interactions in other
MLL-fusion leukemias, but it is reasonable to expect that MLL-
ENL fusions will behave in a similar manner. MLL-AF9 and
MLL-ENL leukemias are highly aggressive, and patients often
suffer from early relapse after treatment (Krivtsov and Arm-
strong, 2007). The most promising current therapeutic for MLL-818 Cell Reports 11, 808–820, May 5, 2015 ª2015 The Authorsfusion leukemias, EPZ-5676, targets the
enzymatic activity of DOT1L. Not surpris-
ingly, due to its genome-wide role in regu-
lation of transcription, DOT1L inhibition
has an effect on many genes, the long-
term effects of which is not yet clear (Dai-
gle et al., 2013). We propose that the
DOT1L interactions with either AF9 or
ENL would be excellent therapeutic
targets for MLL-AF9 and MLL-ENL leuke-
mias. Blocking this protein-protein
interaction is likely to have distinct advan-
tages over inhibiting DOT1L enzymatic
activity, as only a very limited number of
MLL-AF9 target genes show significant
losses in H3K79 methylation marks;
thus, the scale of the effects on gene expression would be limited
to these genes and those that are targets of wild-type AF9 and
ENL regulation.
EXPERIMENTAL PROCEDURES
DOT1L-AF9 Assignments, Structure Determination, and Refinement
All proteins were cloned, expressed, and purified according to standard
methods, and constructs were optimized as described previously (Leach
et al., 2013). For all NMR experiments, assignments and calculations were
made using standard methods. Details are provided in Supplemental Experi-
mental Procedures.
Protein Binding Measurements, Co-immunoprecipitation, and
Western Blots
Fluorescence polarization based binding measurements were performed as
previously described (Leach et al., 2013). Co-immunoprecipitation experi-
ments were conducted using HEK293 cells that were cotransfected with
3xFLAG-AF9 (WT, D544R, or D546Rmutant) C-terminal amino acid fragments
376–568 or 470–568, andGFP-tagged full-length Dot1l, DOT1L (828–1095) en-
compassing both sites 2 and 3, DOT1L (479–659) including site 1, full-length
CBX8, or AF4 (647–871) encompassing the AF9 interaction domain. Details
are provided in Supplemental Experimental Procedures.
Serial Replating Assays
All studies involving mice were approved by Loyola University’s Institutional
Animal Care and Use Committee, according to standards set forth in the
National Institutes of Health Guidelines. MLL-AF9 wild-type and MLL-AF9
mutant serial replating assays were conducted with murine bone marrow c-
kit+ cells transduced with MSCVneo, MSCVneo-MLL-AF9 (WT), MSCVneo-
MLL-AF9 (D544R), or MSCVneo-MLL-AF9 (D546R) retroviruses. For DOT1L
mutant serial replating assays, full-length DOT1L, either wild-type or contain-
ing alanine mutations, was cloned into an MSCV-mCherry retroviral vector.
See Supplemental Experimental Procedures for further details and for primer
sequences.
Quantitative RT-PCR
Cells were harvested from methylcellulose colony assays after 1 week, RNA
was isolated, and cDNAwas synthesized. Quantitative real-time PCRwas per-
formed using TaqMan probes for Hoxa9, Meis1, Gfi1, Myb, Cdk6, and Eya1
(Applied Biosystems), and data were analyzed using the 2DD Ct method.
Expression was normalized to Gapdh expression and was performed in
triplicate.
ChIP-Seq Experiments
Small scale ChIP experiments for histone H3 lysine 79 dimethylation
(H3K79me2, Abcam ab3594) and trimethylation marks (H3K79me3, Diage-
node cat# pAb-068-050) were carried out using previously published mini
ChIP protocol (Adli and Bernstein, 2011). ChIP-seq data can be accessed un-
der accession number GSE64365 in the Gene Expression Omnibus. Details
are provided in the Supplemental Experimental Procedures.
ACCESSION NUMBERS
The PDB accession number for the DOT1L-AF9 NMR solution structure is
2mv7. The BMRB accession number for the NMR data is 19516. ChIP-Seq
data can be accessed under accession number GSE64365 in the Gene
Expression Omnibus.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2015.04.004.
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